Any guesses on what it could be about the infusion pump compared to the intratumoural injection that could overcome the low permeability of brain tissue to fluid diffusion you mentioned, such that more reovirus could be deliverd into greater proximity to the max amount of cancerous growth?
Do you have any feel or guess as to how much of a limiting factor low permeability of brain tissue to fluid diffusion has been in the HC trial? After all, at least 3 patients demontrated (and may still be demonstrating) life extension. Although, it's possible the LE might not be related. But probably has something to do with it.
At the very least they seem to have isolated what they are up against in terms of effective delivery into the brain. And perhaps the approval for U.S trial delay ends up working in their favor... Would they have used the infusion pump if this trial had been approved 3 years ago?
Market Data 
Markets 
AI
